BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22568394)

  • 1. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs.
    Mochel JP; Peyrou M; Fink M; Strehlau G; Mohamed R; Giraudel JM; Ploeger B; Danhof M
    J Vet Pharmacol Ther; 2013 Apr; 36(2):174-80. PubMed ID: 22568394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned?
    Mochel JP; Danhof M
    Rev Physiol Biochem Pharmacol; 2015; 169():43-69. PubMed ID: 26428686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
    Mochel JP; Fink M; Peyrou M; Soubret A; Giraudel JM; Danhof M
    Pharm Res; 2015 Jun; 32(6):1931-46. PubMed ID: 25446774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs.
    Lantis AC; Ames MK; Atkins CE; DeFrancesco TC; Keene BW; Werre SR
    J Vet Pharmacol Ther; 2015 Feb; 38(1):65-73. PubMed ID: 25224804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.
    Lantis AC; Ames MK; Werre S; Atkins CE
    J Vet Pharmacol Ther; 2015 Oct; 38(5):513-7. PubMed ID: 25771846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs.
    Sotillo S; Ward JL; Guillot E; Domenig O; Yuan L; Smith JS; Gabriel V; Iennarella-Servantez CA; Mochel JP
    Sci Rep; 2023 Feb; 13(1):2684. PubMed ID: 36792677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
    King JN; Mauron C; Kaiser G
    Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.
    Ames MK; Atkins CE; Lantis AC; zum Brunnen J
    J Renin Angiotensin Aldosterone Syst; 2016; 17(1):1470320316633897. PubMed ID: 27009288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of spironolactone and benazepril on furosemide-induced diuresis and renin-angiotensin-aldosterone system activation in normal dogs.
    Adin D; Atkins C; Wallace G; Klein A
    J Vet Intern Med; 2021 May; 35(3):1245-1254. PubMed ID: 33713485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of urinary aldosterone measurement in quantitating RAAS activation.
    Atkins CE; Lantis AC; Ames MK; Gardner SY
    J Vet Pharmacol Ther; 2012 Oct; 35(5):512-5; author reply 516-8. PubMed ID: 22966900
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.
    Ames MK; Atkins CE; Lee S; Lantis AC; zumBrunnen JR
    Am J Vet Res; 2015 Dec; 76(12):1041-50. PubMed ID: 26618728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology.
    Mochel JP; Fink M; Peyrou M; Desevaux C; Deurinck M; Giraudel JM; Danhof M
    Chronobiol Int; 2013 Nov; 30(9):1144-59. PubMed ID: 23931032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK; Atkins CE; Eriksson A; Hess AM
    J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin aldosterone profile before and after angiotensin-converting enzyme-inhibitor administration in dogs with angiotensin-converting enzyme gene polymorphism.
    Adin D; Atkins C; Domenig O; DeFrancesco T; Keene B; Tou S; Stern JA; Meurs KM
    J Vet Intern Med; 2020 Mar; 34(2):600-606. PubMed ID: 32112596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine.
    Schneider BK; Ward J; Sotillo S; Garelli-Paar C; Guillot E; Prikazsky M; Mochel JP
    Sci Rep; 2023 Feb; 13(1):3300. PubMed ID: 36843132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the renin-angiotensin-aldosterone system for control of arterial blood pressure following moderate deficit in total body sodium: balance studies in freely moving dogs.
    Seeliger E; Lunenburg T; Ladwig M; Reinhardt HW
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):e43-51. PubMed ID: 19930429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J; Hansson K; Karlberg BE; Kvart C; Madej A; Olsson K
    Am J Vet Res; 1996 Nov; 57(11):1645-52. PubMed ID: 8915446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
    van den Heuvel M; Batenburg WW; Jainandunsing S; Garrelds IM; van Gool JM; Feelders RA; van den Meiracker AH; Danser AH
    J Hypertens; 2011 Nov; 29(11):2147-55. PubMed ID: 21941204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
    Sakatani A; Miyagawa Y; Takemura N
    J Vet Cardiol; 2016 Sep; 18(3):248-254. PubMed ID: 27364087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.